

RIBAPHARM INC  
Form 8-K  
May 01, 2003

---

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of the Earliest Event Reported: May 1, 2003

Date of Report: May 1, 2003

**RIBAPHARM INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of

1-31294

(Commission

95-4805665

(I.R.S. Employer

Edgar Filing: RIBAPHARM INC - Form 8-K

(Incorporation or organization)

(File number)

(Identification No.)

3300 Hyland Avenue

Costa Mesa, California 92626

(Address of principal executive offices) (Zip code)

(714) 427-6236

(Registrant's telephone  
number, including area code)

---

Edgar Filing: RIBAPHARM INC - Form 8-K

Item 7. Financial Statements and Exhibits.

(c) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated May 1, 2003

Item 9. Regulation FD Disclosure.

The following information is furnished pursuant to Item 12, Disclosure of Results of Operations and Financial Conditions.

On May 1, 2003, Ribapharm Inc. issued a press release announcing its first fiscal quarter results ended March 31, 2003 and will hold a conference call on such date. The press release is attached as Exhibit 99.1.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Ribapharm Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 1, 2003

RIBAPHARM INC.

/s/ Kim D. Lamon

---

**President and Chief Executive Officer**